A phase II randomized clinical trial to evaluate the safety and feasibility of fecal microbiota transplantation (FMT) in patients with stage II-III non-small cell lung cancer (NSCLC), using patients who have responded to immune checkpoint inhibitors (ICIs) as donors. MIGRANT.
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: GECP FOUNDATION
- Phase: II
- Execution start: 07/11/2025
- End of execution: 30/03/2032
- IP: SILVIA SEQUERO LOPEZ
